SBIR/STTR Research Award

Gene Delivery Agents for Ultrasound-Mediated Transfection

Award identifier 5fa7483cf6add41b67d11b4511147435ca58953690077bf2b9ffc4dc98441dadAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$99,867

Program and phase

SBIR · Phase I

Award year

2007

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
TARGESON, INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
Not reported
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): We propose to develop a novel acoustically activated microbubble gene delivery vehicle for treatment of experimental inflammatory bowel disease. Microbubble ultrasound contrast agents composed of a cationic lipid shell are targeted to the adhesion molecule MAdCAM-1 by a monoclonal antibody immobilized to the surface of the agent. Plasmid DNA is coupled to the cationic surface of the agent via electrostatic interaction. Microbubbles are administered intravenously and accumulate at sites of intravascular MAdCAM-1 expression, corresponding to inflammatory foci. DNA is released from the agents at the target site by ultrasound-mediated microbubble destruction using a clinical ultrasound scanner. This method has shown efficacy for transfecting reporter genes to perivascular tissue in mice and rats. This strategy offers a safe, non-viral, non-invasive method of delivering genetic material in vivo. Selectivity is accomplished by targeting the agents to a molecular marker of inflammation, and ultrasound-mediated microbubble destruction is required for release of DNA from the agent surface. The stability of these gene delivery vehicles will be examined to assess the feasibility for commercial scale production of a research-grade tool for gene delivery. The ability of these agents to selectively transfect inflamed bowel will be examined using a luciferase reporter gene and bioluminescence imaging in a mouse model of inflammatory bowel disease. This project will result in the development of a novel and efficient gene delivery tool for pre-clinical research, which can eliminate the need for problematic viral vectors and invasive electroporation techniques. Additionally, this work has the potential to translate into a clinically viable method of treatment for inflammatory bowel disease. Gene therapy offers a treatment modality for Crohn's disease, for which only symptomatic treatment is currently available. Ultrasound-mediated microbubble gene delivery is a safe, non-viral, non-invasive and high- efficiency method of transfection. The development of targeted ultrasound-activated microbubble gene delivery vehicles presents a novel and effective method of accomplishing gene transfer in pre-clinical research. This technique will offer an alternative to viral and invasive electroporation transfection techniques, and offers a potential mode for accomplishing gene delivery in a clinical setting using existing ultrasound equipment.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.